An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
about
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer
P2860
Q33912075-2921A332-EF82-4D4E-8F2F-5E188903922DQ36382143-55251962-9DB7-4833-B259-5927E199F635Q41668880-941A8A88-CB9B-4112-BE54-940EB38DD871Q41849636-1C59EAF4-80DA-447A-8EC8-064C6ED1BEDBQ47120629-12D47FBE-8437-4857-8CD8-4F77409CFC1EQ47132253-C62CB03C-73B4-4A7C-A2BF-E2D5D4061D11Q47329066-DE7A8246-0EF9-4DFE-A48A-63E171330466Q47424027-2D1E9CAD-79A5-4AA5-8623-359DD261014DQ47783661-39DFE931-6D84-4BC4-9531-ADA0E8A777EFQ52630284-7E7C25FE-1FE3-469B-B12C-F370681ED867Q53818892-AEE074BA-9896-4F7B-BCD8-4B906CE0A574Q55394825-ACEBDBB9-68B1-4DD4-AC6A-EF202F745D24Q56888862-EC4E1944-DDB4-4FE1-BFCA-94D252B4AC5CQ58770914-92E75638-D04C-41A6-889C-9069880215DD
P2860
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@en
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@nl
type
label
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@en
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@nl
prefLabel
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@en
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@nl
P2093
P2860
P50
P356
P1476
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.
@en
P2093
Fuquan Yang
Jianxun Qi
Jinghua Yan
Qihui Wang
William J Liu
Xiaodong Zhu
P2860
P2888
P356
10.1038/NCOMMS14369
P407
P577
2017-02-06T00:00:00Z